Lantern Pharma's total assets for Q3 2025 were $13.63M, a decrease of -21.78% from the previous quarter. LTRN total liabilities were $4.04M for the fiscal quarter, a -17.52% a decrease from the previous quarter. See a summary of the company’s assets, liabilities, and equity.